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Antimicrobial stewardship is a cornerstone of efforts to curtail antimicrobial resistance 27 
dissemination. However, little is known about factors potentially influencing likelihood of 28 
companion animal antimicrobial prescription. Here, we analysed unwell canine (n=155,732 29 
unique dogs, 281,543 consultations) and feline (n=69,236 unique cats, 111,139 consultations) 30 
electronic health records (EHRs) voluntarily contributed by 173 UK veterinary practices, 31 
using multivariable mixed effects logistic regression. Preventive health-focused owner care 32 
decisions including vaccination (dogs: odds ratio, OR 0.93, 95% confidence interval, CI, 33 
0.90-0.95; cats: OR 0.92, CI 0.89-0.95), insurance (dogs: OR 0.87, CI 0.84-0.90; cats: OR 34 
0.82, CI 0.79-0.86) or neutering in dogs (OR 0.90, CI 0.88-0.92) were associated with 35 
decreased systemic antimicrobial prescription odds, as were dogs presenting to Royal College 36 
of Veterinary Surgeons accredited practices (OR 0.79, CI 0.68-0.92). This large multi-centre 37 
companion animal EHR study successfully demonstrated the potential of preventive 38 
healthcare and owner engagement to encourage responsible antimicrobial use. 39 
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Antimicrobial use is a key driver in the promotion and transmission of antimicrobial 48 
resistance (AMR) in humans, livestock (e.g. chickens, pigs etc.), and companion animals (e.g. 49 
dogs and cats) (1-5). Of these groups, the important role of companion animals for 50 
development (1,2), carriage (6) and transmission of AMR bacteria both within animal 51 
populations and to/from humans, due at least in part to the close proximity in which 52 
companion animals reside with humans (5,7,8), is now being increasingly realised. Indeed, 53 
companion animals are now included in recent global action plans aimed at tackling the 54 
important global AMR health threat (9). 55 
 56 
Both electronic health records (EHRs) and qualitative research techniques have been used 57 
extensively in human medicine to identify many practitioner and patient-led factors 58 
associated with antimicrobial prescription likelihood (10-13). In veterinary medicine, studies 59 
investigating antimicrobial prescribing practices and related risk factors are more limited 60 
(14). To date, companion animal research has largely focused on postal surveys (15,16) and 61 
in-person interviews (17) to explore perceptions held by veterinary practitioners. However, 62 
recent veterinary health informatics advances have provided opportunities to utilise 63 
veterinary EHRs at scale to survey antimicrobial prescription (18,19). 64 
 65 
Thus far, key insights into antimicrobial prescription frequency and variety have been 66 
demonstrated (20-23), including an apparent increase in feline cefovecin use (21,22), a third 67 
generation cephalosporin considered ‘highest priority critically important’ (HPCIA) by the 68 
World Health Organization (24). Considerable inter-practice (20,22) regional (21) and 69 
clinical presentation (22,25,26) variability in antimicrobial prescription frequency and choice 70 




opinion over when antimicrobial therapy is justified, and which antimicrobial classes would 72 
then be most appropriate (15-17), why such observed variation exists is currently unknown. 73 
 74 
There remains a need to identify factors potentially influencing antimicrobial prescribing in 75 
the clinical environment. This study utilised the EHRs of a large, diverse veterinary-visiting 76 
population of dogs and cats collected from a network of volunteer first-opinion veterinary 77 
practices across Great Britain. We explored associations between antimicrobial prescription 78 
(including antimicrobials authorised for systemic administration; antimicrobials authorised 79 
for topical administration, and HPCIAs) and a range of veterinary practice, practitioner, 80 
owner, and animal-related factors (including socioeconomic factors and preventive healthcare 81 
interventions) in animals recorded as primarily presenting for investigation of disease. 82 
 83 
Materials and methods 84 
Data collection 85 
This cross-sectional study used EHRs from 178 volunteer veterinary practices (386 unique 86 
sites) taking part in the Small Animal Veterinary Surveillance Network (SAVSNET, 87 
University of Liverpool ethical approval reference: RETH000964), utilising the Robovet 88 
practice management system (Vet Solutions Ltd.). EHRs were retrieved from booked 89 
consultations (19) between 1st April 2014 and 31st March 2016. Each consultation record 90 
included species, breed, sex, neuter status, insurance status, microchip status, vaccination 91 
history, date of birth, owner’s postcode and any products dispensed at time of consultation. 92 
Every consultation record was further classified by the attending veterinary professional into 93 
one of ten main presenting complaints (MPCs) (grouped into ‘healthy’; ‘unhealthy’, or ‘post-94 
operative’ categories), indicating the main reason the animal was presented to the veterinary 95 





Data management 98 
General data management 99 
There were 762,648 canine and 300,606 feline consultations initially available. Animals with 100 
likely incorrectly recorded dates of birth (dogs and cats exceeding 24.5 and 26.0 years of age 101 
at consultation, respectively) were excluded (n canine = 1,577; n feline = 2,467), as were 102 
animals lacking a valid owner’s postcode (n canine = 23,705; n feline = 9,901). Only 103 
consultations where animals were recorded as unhealthy (hence, ‘sick animal consultations’) 104 
by MPC were used in this study (282,263 out of 737,366 remaining canine consultations and 105 
111,367 out of 288,238 remaining feline consultations). Veterinary practices (n=5) providing 106 
insufficient EHRs for adequate statistical analyses (less than 50 consultations) were also 107 
removed. 108 
 109 
Antimicrobial prescription was identified via the text-based product description and classified 110 
into systemic (oral or injectable) or topical (topical, aural, ocular) administration routes, using 111 
a semi-automated rule-based text-mining method as previously described (22). All 112 
fluoroquinolones, macrolides and third generation cephalosporins were considered HPCIAs 113 
(24). Antimicrobials authorised for dog and/or cat use in the UK are summarised in 114 
Supplementary material, Table S1. 115 
 116 
Animal factors 117 
Animals were considered vaccinated if the most recently recorded vaccination date 118 
(disregarding vaccine composition) was less than or equal to 3.5 years (broadly reflective of 119 
current vaccine interval guidelines) before the relevant consultation date (27). Breeds were 120 




similar breed groups (29), crossbreeds, breeds not yet genetically classified (‘unclassified’), 122 
or breed not recorded/recognisable (‘unknown’). 123 
 124 
Owner factors 125 
Using pet owner’s home postcode, a measure of predicted deprivation was assigned to each 126 
owner using the most recent English 2015, Scottish 2012 and Welsh 2014 Indices of Multiple 127 
Deprivation (IMD). As IMD measures between countries are not directly comparable, 128 
country was included in statistical models as a three-level factor and each country's complete 129 
set of IMD ranks were rescaled to the range 0 to 1, with 1 corresponding to the least deprived 130 
area. 131 
 132 
We determined country of residence and urban/rural status via reference to the National 133 
Statistics Postcode Look-up. The recorded centroid associated with each postcode was 134 
utilised to place each animal owner within a 1 km2 gridded cell, and each EHR was hence 135 
associated with an estimate of the number of dogs or cats within each 1 km2 gridded cell as 136 
defined by Aegerter et al. (2017). Finally, postcode district was used to provide an estimate of 137 
the number of dogs or cats per household for each recorded postcode (30). 138 
 139 
Veterinary practice and practitioner factors 140 
The RCVS Practice Register was utilised (interrogated 18th October 2016) to summarise each 141 
veterinary practice by advertised treated species range into four categories: companion 142 
animal; mixed (companion animal, large animal and equine); companion and large animal; 143 
and companion animal and equine. Practices were considered accredited under the voluntary 144 
RCVS Practice Standards Scheme (PSS) if at least one site was recorded as accredited (Core 145 




practices contained a Veterinary Hospital site. Practices listing ‘referrals’ as an interest were 147 
also recorded. Practices employing at least one veterinary surgeon holding ‘RCVS Advanced 148 
Veterinary Practitioner (AVP)’ status or separately ‘RCVS specialist’ status in areas of 149 
relevance to companion animals were also recorded. 150 
 151 
Statistical analysis 152 
The statistical programme ‘R’ was used for all analyses. Descriptive proportions and 153 
confidence intervals were adjusted for clustering within sites (bootstrap method, n=5,000 154 
samples) (31). Univariable and multivariable mixed effects logistic regression models were 155 
fitted separately in dogs and cats using the R package ‘lme4’ (32). Likelihood ratio tests 156 
(LRT), Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), and 157 
evidence of inter-practice antimicrobial prescription frequency variation (22) indicated that 158 
observations were clustered within veterinary practice, site and animal; therefore, all three 159 
factors were included as random intercepts in all models. Separate analyses were undertaken 160 
to assess the association between explanatory variables and three binary outcomes of interest: 161 
antimicrobial prescription authorised for systemic administration (‘systemic antimicrobial’); 162 
topical administration (‘topical antimicrobial’); and systemically administered HPCIAs. 163 
 164 
Initial univariable screening included fifteen categorical variables (sex, neutered status, 165 
microchip status, insurance status, vaccination status, genetic breed group, country of 166 
residence, owner urban/rural status, MPC, treated species (‘practice type’), RCVS 167 
accreditation, RCVS Veterinary Hospital, referral interest, RCVS AVP, and RCVS 168 
specialist), and four continuous variables (age at consultation, rescaled IMD rank (‘rIMD’), 169 
dog or cat population per km2, and mean number of dogs or cats per household at district of 170 




if an LRT, AIC and BIC indicated significantly improved fit, compared to linear and lesser 172 
polynomial terms. Explanatory variables were retained for multivariable analysis if an LRT 173 
indicated P≤0.20 against a null model. 174 
 175 
Multivariable models underwent manual step-wise backward elimination to minimise AIC 176 
and BIC. A two-way interaction between rIMD and the three-level factor country was 177 
included in the initial multivariable model (deleted if AIC and BIC decreased upon removal), 178 
with country alone as a false intercept. Confounding was accounted for via assessment of 179 
effect variation upon removal of variables. Two-way interaction terms between other 180 
explanatory variables were assessed via AIC, BIC and an LRT. The Variance Inflation Factor 181 
(VIF) was used to assess multicollinearity (33). For continuous variables, projected 182 
prescription probabilities and associated 95% confidence intervals were calculated from log 183 
odds using ‘sjPlot’ (34). Statistical significance was defined as P<0.05. 184 
 185 
Results 186 
Data from 281,543 sick dog (155,732 unique dogs) and 111,139 sick cat (69,236 unique cats) 187 
consultations from 173 veterinary practices (379 sites) were analysed. A descriptive 188 
population summary is included in Table 1, and a summary of genetic breed groups included 189 
in this study is included in Supplementary material, Table S2. 190 
 191 
Dogs 192 
Antimicrobial prescription 193 
Systemic antimicrobials, topical antimicrobials, or systemic HPCIAs were prescribed in 194 
25.7% (95% Confidence Interval, CI, 24.9-26.6), 14.2% (CI 13.9-14.6) and 1.4% (CI 1.2-1.6) 195 




class (0.9% of sick consultations, CI 0.7-1.0), followed by 3rd generation cephalosporins 197 
(0.5%, CI 0.4-0.6) and macrolides (0.1%, CI 0.0-0.2). Antimicrobial prescription summarised 198 
by commonly consulted breed is summarised in Supplementary material, Table S3. 199 
 200 
Systemic antimicrobial prescription 201 
Descriptive analyses and univariable model results are summarised in Supplementary 202 
material, Table S4. Final multivariable model results are available in Table 2. Vaccinated or 203 
neutered dogs were less likely to receive a systemic antimicrobial prescription compared to 204 
unvaccinated or un-neutered dogs. Insured dogs were less likely than uninsured dogs to be 205 
prescribed a systemic antimicrobial up to approximately 12 years of age (Figure 1a). The 206 
respiratory MPC was associated with greatest prescription odds compared to the gastroenteric 207 
MPC. Mixed practices were associated with significantly increased prescription odds 208 
compared to practices treating companion animals only. RCVS accredited practices were less 209 
likely to prescribe a systemic antimicrobial. 210 
 211 
Systemic HPCIA prescription 212 
Descriptive analyses and univariable model results are summarised in Supplementary 213 
material, Table S5. Final multivariable model results are available in Table 3. Vaccinated or 214 
insured dogs were less likely to be prescribed a systemic HPCIA. The respiratory MPC 215 
showed the greatest odds of prescription. Odds increased with age in dogs (Figure 2a). 216 
Compared to the retriever, the toy genetic breed group was associated with the greatest odds 217 
of systemic HPCIA prescription. 218 
 219 




Descriptive analyses and univariable model results are summarised in Supplementary 221 
material, Table S6. Final multivariable model results are available in Table 4. Insured dogs 222 
were less likely to be prescribed a topical antimicrobial, though male, microchipped, or 223 
vaccinated dogs displayed significantly increased prescription odds. The effect of age was 224 
varied according to MPC; the pruritus MPC was generally associated with greatest 225 
prescription odds throughout life, broadly decreasing with increased age (Figure 3a). 226 
Compared to the retriever, sight hounds displayed the smallest prescription odds. Practices 227 
employing RCVS specialists were less likely to prescribe a topical antimicrobial. 228 
 229 
Cats 230 
Antimicrobial prescription 231 
Systemic antimicrobials, topical antimicrobials or systemic HPCIAs were prescribed in 232 
32.9% (CI 31.9-33.8), 6.1% (CI 5.9-6.3) and 17.3% (CI 16.2-18.4) of consultations. The most 233 
commonly prescribed systemic HPCIA class were 3rd generation cephalosporins (16.4% of 234 
sick consults, CI 15.3-17.6), followed by fluoroquinolones (0.7%, CI 0.4-0.9) and macrolides 235 
(0.03%, CI 0.0-0.05). Antimicrobial prescription summarised by commonly consulted breed 236 
is summarised in Supplementary material, Table S7. 237 
 238 
Systemic antimicrobial prescription 239 
Descriptive analyses and univariable model results are summarised in Supplementary 240 
material, Table S8. Final multivariable model results are available in Table 5. Vaccinated or 241 
insured cats had significantly reduced odds of systemic antimicrobial prescription. The 242 
respiratory and trauma MPCs were associated with greatest prescription odds, though there 243 
was a significant interaction between sex and MPC, with male cats significantly more likely 244 




generally associated with reduced odds until approximately 15 years of age, when females 246 
were then associated with increased odds compared to male cats (Figure 1b). Compared to 247 
practices treating companion animals only, mixed practices were more likely to prescribe a 248 
systemic antimicrobial. 249 
 250 
Systemic HPCIA prescription 251 
Descriptive analyses and univariable model results are summarised in Supplementary 252 
material, Table S9. Final multivariable model results are available in Table 6. Vaccinated or 253 
insured cats were less likely to be prescribed a systemic HPCIA. Though the respiratory MPC 254 
showed the greatest odds, RCVS accredited practices were associated with increased odds for 255 
cats presenting with trauma. Prescription probability increased up to 6-9 years of age before 256 
reducing until approximately 18 years of age and increasing again hereafter; compared to 257 
females, males were more likely to be prescribed between 5 and 14 years of age (Figure 2b). 258 
Compared to the West Europe genetic breed group, the Asian group was associated with the 259 
greatest odds of systemic HPCIA prescription. 260 
 261 
Topical antimicrobial prescription 262 
Descriptive analyses and univariable model results are summarised in Supplementary 263 
material Table 10. Final multivariable model results are available in Table 7. Insured cats 264 
were less likely to be prescribed a topical antimicrobial. The effect of age at consultation 265 
varied according to MPC; in pruritic cats there was a decreasing prescription probability until 266 
approximately 7 years of age, before increasing again (Figure 3b). Compared to the West 267 






Here we have demonstrated frequent antimicrobial prescription including systemic HPCIAs 271 
(particularly in cats), in veterinary practices in the UK. Considering the importance of 272 
HPCIAs in the context of AMR (35), we have identified a vital need to understand more 273 
about factors potentially driving such prescribing behaviours. We have further augmented 274 
EHR data using a range of external data sources to identify key owner, animal and practice-275 
related risk factors associated with systemic and topical antimicrobial, and systemic HPCIA, 276 
prescription; such factors potentially informing key antimicrobial stewardship targets of 277 
importance to companion animal practice. 278 
 279 
Regarding owner care decision-related factors, vaccinated dogs and cats were associated with 280 
significantly reduced systemic antimicrobial and HPCIA prescription odds, possibly 281 
reflecting perceived or actual reduced risk of antimicrobial-responsive disease in vaccinated 282 
animals. Though most companion animal vaccines target viruses, bacterial infection 283 
secondary to vaccine-preventable viral disease is documented (36). Risk avoidance plays an 284 
important role in antimicrobial prescribing practices (12), potentially prompting more 285 
frequent prescription in unwell, unvaccinated animals. We speculate that previous 286 
engagement with preventive healthcare might select for owners more likely to seek veterinary 287 
attention earlier and/or to pursue diagnostic options in preference to empirical prescription. 288 
Regardless of what might be driving these trends, the O’Neill Report has recommended that 289 
promoting development and use of vaccines and alternatives to antibiotics should form a key 290 
component of efforts to curtail human AMR dissemination (37); our findings suggest that 291 
such recommendations should also be considered for companion animals. 292 
 293 
Presence of insurance was also associated with decreased systemic and topical antimicrobial 294 




wider range of diagnostic options in preference to empirical antibiosis in insured animals. 296 
However, insured dogs were also associated with increased systemic HPCIA prescription 297 
odds. Cost of therapy has been shown to influence companion animal antimicrobial agent 298 
choice (17), and HPCIAs are anecdotally considered a more expensive option compared to 299 
other antimicrobials. Hence, our findings might reflect increased willingness to prescribe 300 
relatively expensive antimicrobials to insured dogs. 301 
 302 
Though HPCIA classification remains under debate, HPCIA use has formed a focus for 303 
AMR-related policy (37). Whilst a number of HPCIA classes (e.g. glycopeptides, which are 304 
not authorised for use in animals) are very rarely prescribed to companion animals in the UK 305 
(22), prescription of fluoroquinolones and 3rd generation cephalosporins (particularly in cats) 306 
is relatively commonplace, though current antimicrobial prescribing guidance strongly 307 
discourages such practices (38). 308 
 309 
Considering animal-intrinsic factors, male cats were associated with increased systemic 310 
antimicrobial prescription odds in younger animals, though the opposite was found for dogs. 311 
Sex-based variation in bacterial infection risk has been previously identified (39-41), and cat 312 
fight-related injuries are a frequently recorded clinical complaint (42) more commonly 313 
associated with young outdoor-ranging male cats (43). Indeed, here we found male cats 314 
presenting with trauma to be more commonly prescribed systemic antimicrobials. Further, 315 
time of injury is less likely to be known in outdoor ranging cats compared to dogs; such 316 
uncertainty might well prompt a more cautious antimicrobial prescribing approach (44).  317 
 318 
Other studies have also identified age- or sex-related variation in AMR risk (39-41). For 319 




probability with increased age (20), potentially reflecting increased actual or perceived non-321 
communicable disease incidence as animals age. This interpretation might partly explain our 322 
findings, though a notable exception was observed - systemic HPCIA prescription. In cats an 323 
easy-to-administer (injectable) long-acting 3rd generation cephalosporin formulation is widely 324 
used (21-23). Although not completely explanatory, our findings may suggest that as an 325 
animal ages the owner or veterinary surgeon perceives an increased probability of an animal 326 
being refractory to an intervention (e.g. administering oral tablets), increasing the likelihood 327 
of a prescriber choosing easy-to-administer formulations. Provision of inappropriate dosages 328 
as a result of non-compliance has been previously identified as a key influencer of 329 
antimicrobial agent choice (17). Deciding whether the AMR risk posed by a possible under-330 
dose of a first-line antimicrobial outweighs the AMR risk posed by the labelled dose of a 331 
third-line HPCIA remains an important unanswered question in companion animal practice. 332 
 333 
As with humans (10,11,13), respiratory clinical signs were most commonly associated with 334 
systemic antimicrobial prescription in dogs and cats. Humans suffering from respiratory 335 
conditions are often inappropriately prescribed antimicrobials, the majority of such 336 
conditions being viral or non-infectious in origin (10). This has also been shown for 337 
companion animals, though bacterial sequelae to primary viral disease has been documented 338 
(45). Considering these shared patterns, although prescribing guidance is available (46), we 339 
suggest respiratory disease as a pertinent area for further investigation of ‘one health’ 340 
stewardship intervention methods. 341 
 342 
The retriever group, containing a number of breeds commonly associated with dermatological 343 
disease (47), was associated with increased odds of topical antimicrobial prescription. This 344 




employed here to combat the modelling issues posed by over recorded 250 dog and 50 cat 346 
breeds in this dataset was useful. However, it should be remembered that genetic linkage does 347 
not necessarily imply phenotypic similarity. As such, individual breed-level phenotypes 348 
might be responsible for conferring variant bacterial infection risk in ways not explored, and 349 
indeed potentially masked, here. We aim to identify additional means by which breeds can be 350 
effectively summarised according to both shared genotype and phenotype for future analyses. 351 
 352 
Although the individual animal accounted for the majority of random effect variance seen 353 
here, veterinary-led factors might well yield more readily accessible routes towards 354 
stewardship. The voluntary RCVS PSS requires antimicrobial usage policies, infection 355 
control plans, and established clinical audit for site accreditation (48), and here we observed 356 
reduced canine systemic antimicrobial prescription odds in accredited practices. Though 357 
practices seeking accreditation might already be more engaged with quality improvement, we 358 
would nevertheless recommend further consideration as to whether the RCVS PSS could play 359 
a more central role for encouraging stewardship in both first opinion and referral practice. 360 
 361 
Compared to practices only treating companion animals, mixed species practices were 362 
associated with increased systemic antimicrobial prescription odds. Veterinary surgeons 363 
employed in different sectors express varied attitudes towards AMR (16); a finding perhaps 364 
demonstrated at scale here. Practices employing RCVS specialists were also associated with 365 
reduced topical antimicrobial prescription odds in dogs, potentially reflecting varied case 366 
management approach (49) or caseload compared to first opinion practices. 367 
 368 
Considering limitations of this study, although we successfully augmented EHRs with a 369 




employment record of the RCVS Practice Register is updated only on an ad hoc basis. It is 371 
thus possible that the surveyed veterinary surgeon population varied over the two-year study 372 
period in ways not captured here. Veterinary practices participating in SAVSNET are 373 
recruited by convenience and might not be representative of the wider UK population. 374 
Though no clear associations between IMD or pet population density and prescription were 375 
found here, the complexities of summarising IMD across the devolved constituent countries 376 
of the UK (50), coupled with the relative infancy of pet population demographic studies (30), 377 
lead us to recommend re-evaluation as research methodologies further mature. The analysed 378 
population was relatively skewed towards less deprived areas; to ascertain whether this is 379 
reflective of the wider UK pet owning community, including the charity and low-income 380 
veterinary sectors in future analyses would be warranted. We would advise caution for 381 
inferring causal relationships between factors and outcome variables explored in this cross-382 
sectional study; similarly, group-level observations might have limited relevance to 383 
individual animals. More generalised SAVSNET limitations has been previously discussed; 384 
briefly, antimicrobial prescription quantification depends on practitioners charging for 385 
antimicrobials, and analysed practices were recruited by convenience (22,30). 386 
 387 
Conclusions 388 
We have demonstrated the utility of veterinary EHRs collected from a cohort of veterinary 389 
practices to identify a range of factors associated with canine and feline antimicrobial 390 
prescription. Though factors influencing decision-making remain multifactorial and complex, 391 
our findings suggest that gathering clinical evidence surrounding respiratory disease might be 392 
of importance to stewardship. Preventive healthcare could also play a valuable stewardship 393 
role, and should form the basis of owner-targeted health messaging, as should the RCVS PSS 394 
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Table 1: Descriptive demographic summary of sick canine and feline consultations utilised for 414 
analyses of factors associated with antimicrobial prescription, gathered from a large sentinel 415 
network of UK-based veterinary practices. 416 
Categorical factors 
 Dogs (n = 281,543) Cats (n = 111,139) 
Variable Category % of consults (95% CI 
a) 
% of consults (95% 
CI) 
Country England 86.6 (81.4-91.9) 88.6 (83.8-93.5) 
Scotland 6.1 (3.0-9.1) 4.5 (2.1-6.9) 
Wales 7.4 (2.8-12.0) 7.0 (2.1-6.9) 
Sex Male 51.8 (51.3-52.3) 51.8 (51.3-52.4) 
Neuter status Neutered 64.6 (63.3-65.9) 82.8 (81.7-84.0) 
Microchip status Microchipped 54.4 (52.4-56.3) 37.8 (36.0-39.5) 
Vaccination status Vaccinated 70.0 (68.6-71.3) 52.7 (51.2-54.1) 
Insurance status Insured 33.5 (31.1-35.9) 19.3 (17.3-21.3) 
Owner urban status Urban 63.8 (59.5-68.1) 70.2 (66.2-74.2) 
Main presenting complaint Gastroenteric 11.3 (11.0-11.6) 8.3 (8.0-8.7) 
Respiratory 4.0 (3.8-4.1) 5.5 (5.2-5.8) 
Pruritus 18.0 (17.3-18.6) 10.3 (9.9-10.7) 
Trauma 16.8 (16.1-17.5) 17.0 (16.3-17.7) 
Tumour 6.0 (5.8-6.3) 3.9 (3.6-4.1) 
Kidney disease 0.7 (0.6-0.8) 2.9 (2.5-3.2) 
Other unwell 43.3 (42.0-44.6) 52.1 (50.9-53.4) 
Practice type Mixed 22.7 (15.1-30.3) 18.1 (11.6-24.6) 
Companion animal 70.6 (62.4-78.8) 76.0 (68.9-83.1) 
Companion & equine 2.4 (0.7-4.0) 2.3 (0.7-4.0) 
Companion & large 4.3 (0.4-8.2) 3.5 (0.3-6.8) 
Accreditation True 83.9 (77.1-90.6) 83.5 (76.5-90.5) 
Hospital status True 20.2 (14.4-26.0) 20.0 (14.5-25.5) 
Referral interest True 27.9 (20.9-34.9) 27.3 (20.3-34.2) 
Employed RCVS AVP b True 24.5 (17.2-31.7) 26.7 (19.2-34.2) 
Employed RCVS specialist b True 2.5 (0.8-4.2) 1.9 (0.6-3.1) 
Continuous factors 
Age at consultation Mean 7.1 (7.1-7.2) 9.5 (9.5-9.6) 
Median [min-max] 7.2 [0-22] 9.7 [0-25.9] 
Rescaled Indices of multiple  Mean 0.59 (0.59-0.60) 0.60 (0.60-0.61) 
deprivation (rIMD) rank Median [min-max] 0.62 [0.0-1.0] 0.63 [0.0-1.0] 
Animals per household c Mean 0.59 (0.59-0.59) 0.50 (0.49-0.50) 
Median [min-max] 0.47 [0-6.0] 0.39 [0-3.6] 
Animals per km2 c Mean 399.4 (397.8-401.0) 409.4 (407.0-411.8) 
Median [min-max] 266 [0-4360] 288 [0-5363] 
a 95% Confidence interval 417 
b At least one employed  veterinary surgeon holding Royal College of Veterinary Surgeons (RCVS) Advanced 418 
Veterinary Practitioner (AVP) and / or specialist status 419 




Table 2: Results from a multivariable mixed effect logistic regression model assessing the 421 
association between a range of categorical animal, owner, practitioner and practice-related 422 
factors and the probability of prescribing a systemic antimicrobial in dogs (n = 72,436/281,543 423 
sick consultations). Significant (P<0.05) results are displayed in bold. 424 
Random effect Variance SD a Variable Category β SE b OR c (CI d) P 
Animal 0.57 0.76 Intercept England -0.08 0.08 0.93 (0.80-1.08) - 
Site 0.05 0.23  Scotland -0.06 0.09 0.94 (0.79-1.12) - 
Practice 0.06 0.24  Wales -0.13 0.09 0.88 (0.73-1.05) - 
   Categorical factors 
   Main Gastroenteric - - 1.00 - 
   presenting Kidney disease -0.38 0.06 0.68 (0.61-0.76) <0.01 
   complaint Other unwell -0.94 0.02 0.39 (0.38-0.40) <0.01 
    Pruritus -0.68 0.02 0.51 (0.49-0.53) <0.01 
    Respiratory 0.10 0.03 1.11 (1.06-1.17) <0.01 
    Trauma -0.89 0.02 0.41 (0.40-0.43) <0.01 
    Tumour -1.18 0.03 0.31 (0.29-0.32) <0.01 
   Neuter status Not neutered - - 1.00 - 
   Neutered -0.11 0.01 0.90 (0.88-0.92) <0.01 
   Sex Female - - 1.00 - 
    Male -0.03 0.01 0.97 (0.95-0.99) 0.01 
   Vaccination  Not vaccinated - - 1.00 - 
   status Vaccinated -0.08 0.01 0.93 (0.90-0.95) <0.01 
   Insurance Not insured - - 1.00 - 
   status Insured -0.14 0.02 0.87 (0.84-0.90) <0.01 
   Genetic Retriever  - - 1.00 - 
   breed Ancient / spitz 0.25 0.05 1.28 (1.17-1.40) <0.01 
   group e Crossbreed 0.06 0.02 1.06 (1.03-1.10) <0.01 
    Herding 0.14 0.03 1.15 (1.09-1.22) <0.01 
    Mastiff-like 0.15 0.02 1.16 (1.11-1.21) <0.01 
    Scent hound 0.10 0.04 1.11 (1.03-1.19) <0.01 
    Sight hound 0.31 0.04 1.36 (1.25-1.48) <0.01 
    Small terrier 0.16 0.02 1.18 (1.13-1.22) <0.01 
    Spaniel 0.16 0.02 1.17 (1.13-1.22) <0.01 
    Toy -0.00 0.03 1.00 (0.94-1.05) 0.92 
    Unclassified 0.11 0.02 1.12 (1.07-1.16) <0.01 
    Unknown 0.09 0.05 1.09 (0.99-1.21) 0.075 
    Working dog 0.19 0.03 1.21 (1.15-1.27) <0.01 
   Practice type Companion animal - - 1.00 - 
   Mixed 0.14 0.07 1.15 (1.01-1.30) 0.04 
   Companion & equine -0.05 0.15 0.95 (0.71-1.27) 0.73 
   Companion & large 0.13 0.14 1.14 (0.86-1.50) 0.37 
   Accreditation None - - 1.00 - 
   status 1+ accredited site -0.24 0.08 0.79 (0.68-0.92) <0.01 
   Referral 
interest 
No - - 1.00 - 
   interest Yes -0.10 0.05 0.91 (0.82-1.00) 0.06 
   Continuous factors 
   Age (years) Age - linear -1.12 0.01 0.89 (0.87-0.91) <0.01 
   Age - quadratic -0.09 0.01 0.92 (0.90-0.93) <0.01 
   Age - cubic 0.05 0.01 1.05 (1.04-1.07) <0.01 
   Interaction terms 
   Insurance 
status : Age 
(years) 
Insured : Age 0.08 0.02 1.09 (1.04-1.14) <0.01 
   Status : ge Insured : Age - 
quadratic 
0.03 0.01 1.03 (1.00-1.06) 0.03 
   (years) Insured : Age - cubic -0.03 0.01 0.97 (0.95-1.00) 0.02 
a Standard deviation 425 
b Standard error 426 
c Odds ratio 427 
d 95% Confidence interval 428 




Table 3: Results from a multivariable mixed effect logistic regression model assessing the 430 
association between a range of categorical animal, owner, practitioner and practice-related 431 
factors and the probability of prescribing a systemic HPCIA in dogs (n = 3,971/281,543 sick 432 
consultations). Significant (P<0.05) results are displayed in bold. 433 
Random effect Variance SD a Variable Category β SE b OR 
c (CI d) P 
Animal 3.04 1.74 Intercept England -4.77 0.11 0.01 (0.01-0.01) - 
Site 0.13 0.36  Scotland -4.91 0.21 0.01 (0.01-0.01) - 
Practice 0.44 0.66  Wales -4.88 0.22 0.01  (0.01-001) - 
   Categorical factors  
   Main presenting 
complaint 
Gastroenteric - - 1.00 - 
   Kidney disease 0.11 0.18 1.12 (0.78-1.60) 0.55 
   Other unwell -0.33 0.06 0.72 (0.64-0.80) <0.01 
   Pruritus -0.23 0.07 0.79 (0.70-0.90) <0.01 
   Respiratory 0.29 0.09 1.33 (1.13-1.57) <0.01 
   Trauma -1.16 0.08 0.31 (0.27-0.37) <0.01 
   Tumour -0.92 0.11 0.40 (0.32-0.49) <0.01 
   Vaccination 
status 
Not vaccinated - - 1.00 - 
   Vaccinated -0.10 0.04 0.91 (0.83-0.99) 0.03 
   Insurance status Not insured - - 1.00 - 
   Insured 0.15 0.05 1.16 (1.07-1.27) <0.01 
   Genetic breed  
group e 
Retriever  - - 1.00 - 
   Ancient / spitz 0.12 0.22 1.13 (0.73-1.74) 0.60 
   Crossbreed 0.24 0.08 1.27 (1.09-1.48) <0.01 
   Herding 0.04 0.12 1.04 (0.82-1.32) 0.73 
   Mastiff-like 0.16 0.10 1.17 (0.97-1.43) 0.11 
   Scent hound 0.67 0.13 1.96 (1.52-2.52) <0.01 
   Sight hound 0.43 0.17 1.54 (1.10-2.15) 0.01 
   Small terrier 0.67 0.08 1.96 (1.67-2.29) <0.01 
   Spaniel 0.45 0.08 1.57 (1.33-1.84) <0.01 
   Toy 0.94 0.10 2.56 (2.10-3.12) <0.01 
   Unclassified 0.39 0.09 1.47 (1.24-1.74) <0.01 
   Unknown 0.23 0.22 1.25 (0.81-1.94) 0.31 
   Working dog 0.45 0.11 1.56 (1.27-1.93) <0.01 
   Continuous factors  
   Age (years) Age - linear 0.19 0.04 1.21 (1.12-1.31) <0.01 
   Age - quadratic -0.06 0.03 0.95 (0.90-0.99) 0.03 
   Age - cubic 0.04 0.02 1.04 (1.01-1.08) 0.01 
a Standard deviation 434 
b Standard error 435 
c Odds ratio 436 
d 95% Confidence interval 437 




Table 4: Results from a multivariable mixed effect logistic regression model assessing the 439 
association between a range of categorical animal, owner, practitioner and practice-related 440 
factors and the probability of prescribing a topical antimicrobial in dogs (n = 40,030/281,543 441 
sick consultations). Significant (P<0.05) results are displayed in bold. 442 
Random effect Variance SD a Variable Category β SE b OR c (CI d) P 
Animal 0.55 0.74 Intercept England -4.01 0.07 0.02 (0.02-0.02) - 
Site 0.02 0.14  Scotland -3.88 0.09 0.02 (0.02-0.02) - 
Practice 0.02 0.16  Wales -4.06 0.09 0.02 (0.01-0.02) - 
   Categorical factors 
   Main presenting 
complaint 
Gastroenteric - - 1.00 - 
   Kidney disease 0.71 0.22 2.03 (1.31-3.15) <0.01 
   Other unwell 2.41 0.07 11.18 (9.78-12.79) <0.01 
   Pruritus 3.24 0.07 25.64 (22.39-29.35) <0.01 
   Respiratory 0.63 0.11 1.88 (1.50-2.34) <0.01 
   Trauma 1.35 0.07 3.87 (3.36-4.46) <0.01 
   Tumour 1.15 0.08 3.16 (2.68-3.73) <0.01 
   Sex 
 
Female - - 1.00 - 
   Male 0.07 0.01 1.08 (1.05-1.10) <0.01 
   Microchip status Not microchipped - - 1.00 - 
    Microchipped 0.03 0.01 1.03 (1.00-1.06) 0.02 
   Vaccination status Not vaccinated - - 1.00 - 
   Vaccinated 0.08 0.02 1.08 (1.05-1.11) <0.01 
   Insurance status Not insured - - 1.00 - 
   Insured -0.10 0.02 0.90 (0.88-0.93) <0.01 
   Genetic  
breed  
group e 
Retriever  - - 1.00 - 
   Ancient / spitz -0.14 0.06 0.87 (0.77-0.97) 0.02 
   Crossbreed -0.21 0.02 0.81 (0.78-0.84) <0.01 
   Herding -0.57 0.04 0.57 (0.53-0.61) <0.01 
   Mastiff-like -0.03 0.03 0.97 (0.93-1.03) 0.32 
   Scent hound -0.25 0.04 0.78 (0.71-0.85) <0.01 
   Sight hound -0.92 0.07 0.40 (0.34-0.46) <0.01 
   Small terrier -0.29 0.03 0.75 (0.71-0.79) <0.01 
   Spaniel 0.04 0.02 1.04 (1.00-1.09) 0.08 
   Toy -0.14 0.03 0.87 (0.82-0.93) <0.01 
   Unclassified -0.06 0.03 0.94 (0.89-0.99) 0.011 
   Unknown -0.31 0.06 0.74 (0.65-0.83) <0.01 
   Working dog -0.21 0.03 0.81 (0.76-0.87) <0.01 
   Hospital status None - - 1.00 - 
   1+ hospital site 0.06 0.04 1.07 (0.98-1.16) 0.15 
   Employed RCVS 
AVP f 
None - - 1.00 - 
   1+ AVP 0.08 0.04 1.08 (0.99-1.17) 0.08 
   Employed RCVS 
specialists f 
None - - 1.00 - 
   1+ specialist -0.27 0.09 0.77 (0.64-0.92) <0.01 
   Continuous factors 
   Age (years) Age - linear -0.10 0.09 0.91 (0.76-1.09) 0.30 
   Age - quadratic 0.04 0.04 1.04 (0.98-1.13) 0.39 
   Age - cubic 0.04 0.04 1.04 (0.96-1.13) 0.30 
   Interaction terms 
   Main presenting 
complaint  : Age 
(years) 
Kidney disease : Age -0.33 0.27 0.72 (0.42-1.22) 0.22 
   Other unwell : Age -0.30 0.10 0.74 (0.61-0.89) <0.01 
   Pruritus : Age 0.08 0.10 1.08 (0.89-1.31) 0.42 
   Respiratory : Age -0.01 0.15 0.90 (0.66-1.21) 0.47 
   Trauma : Age 0.01 0.10 1.01 (0.82-1.23) 0.95 
   Tumour : Age -0.15 0.12 0.86 (0.69-1.08) 0.20 
   Kidney disease : Age - quadratic 0.04 0.15 1.04 (0.77-1.40) 0.79 
   Other unwell : Age - quadratic -0.11 0.05 0.90 (0.82-0.98) 0.02 
   Pruritus : Age - quadratic -0.00 0.05 1.00 (0.91-1.09) 0.96 
   Respiratory : Age - quadratic -0.12 0.08 0.89 (0.76-1.03) 0.11 
   Trauma : Age - quadratic -0.02 0.05 0.98 (0.89-1.08) 0.68 
   Tumour : Age - quadratic 0.14 0.06 1.15 (1.02-1.29) 0.02 
   Kidney disease : Age - cubic -0.01 0.11 0.99 (0.79-1.24) 0.94 
   Other unwell : Age - cubic -0.04 0.04 0.97 (0.89-1.05) 0.39 
   Pruritus : Age - cubic -0.06 0.04 0.94 (0.87-1.02) 0.15 
   Respiratory : Age - cubic -0.01 0.07 0.99 (0.86-1.13) 0.84 
   Trauma : Age - cubic -0.03 0.05 0.97 (0.89-1.06) 0.56 
   Tumour : Age - cubic -0.02 0.05 0.98 (0.88-1.08) 0.64 
a Standard deviation 443 
b Standard error 444 
c Odds ratio 445 
d 95% Confidence interval 446 
e Vonholdt et al., 2010 447 




Table 5: Results from a multivariable mixed effect logistic regression model assessing the 449 
association between a range of categorical animal, owner, practitioner and practice-related 450 
factors and the probability of prescribing a systemic antimicrobial in cats (n = 36,521/111,139 451 
sick consultations). Significant (P<0.05) results are displayed in bold. 452 
Random effect Variance SD a Variable Category β SE b OR c (CI d) P 
Animal 0.50 0.70 Intercept England -0.81 0.06 0.45 (0.39-0.50) - 
Site 0.06 0.25  Scotland -0.77 0.10 0.46 (0.38-0.57) - 
Practice 0.08 0.28  Wales -0.55 0.12 0.58 (0.46-0.72) - 
   Categorical factors    
   Main 
presenting 
complaint 
Gastroenteric - - 1.00 - 
   Kidney disease -0.20 0.07 0.82 (0.71-0.94) 0.01 
   Other unwell -0.23 0.04 0.79 (0.73-0.85) <0.01 
   Pruritus -0.37 0.05 0.69 (0.63-0.76) <0.01 
   Respiratory 0.91 0.06 2.48 (2.23-2.77) <0.01 
   Trauma 0.59 0.04 1.80 (1.65-1.97) <0.01 
   Tumour -0.56 0.07 0.57 (0.50-0.65) <0.01 
   Sex 
 
Female - - 1.00 - 
   Male 0.03 0.05 1.03 (0.93-1.14) 0.59 
   Vaccination 
status 
Not vaccinated - - 1.00 - 
   Vaccinated -0.09 0.02 0.92 (0.89-0.95) <0.01 
   Insurance 
status 
Not insured - - 1.00 - 
   Insured -0.19 0.02 0.82 (0.79-0.86) <0.01 
   Genetic  
breed  
group e 
West Europe - - 1.00 - 
   Asian 0.20 0.05 1.22 (1.10-1.36) <0.01 
   Crossbreed 0.14 0.03 1.16 (1.08-1.23) <0.01 
   Mediterranean 0.36 0.26 1.43 (0.86-2.38) 0.17 
   Unclassified 0.11 0.06 1.11 (0.99-1.24) 0.07 
   Unknown 0.13 0.05 1.14 (1.03-1.26) 0.01 
   Practice type Companion animal - - 1.00 - 
   Mixed 0.18 0.08 1.20 (1.03-1.39) 0.02 
   Companion & equine -0.01 0.18 1.00 (0.70-1.41) 0.98 
   Companion & large 0.10 0.17 1.10 (0.80-1.53) 0.56 
   Referral 
interest 
No - - 1.00 - 
   Yes -0.08 0.06 0.92 (0.82-1.04) 0.18 
   Employed 
RCVS AVP f 
None - - 1.00 - 
   1+ AVP -0.10 0.07 0.90 (0.79-1.04) 0.16 
   Continuous factors    
   Age (years) Age - linear -0.38 0.02 0.69 (0.66-0.72) <0.01 
   Age - quadratic -0.08 0.01 0.90 (0.90-0.95) <0.01 
   Age - cubic 0.10 0.01 1.08 (1.08-1.12) <0.01 
   Cats per km2 g Cats per km2 - linear -0.02 0.01 0.98 (0.97-1.00) 0.02 
   Interaction terms    
   Sex : Age 
(years) 
Male : Age -0.10 0.03 0.91 (0.85-0.97) <0.01 
   Male : Age - 
quadratic 
-0.10 0.02 0.91 (0.88-0.94) <0.01 
   Male : Age - cubic 0.03 0.02 1.03 (1.00-1.06) 0.11 
   Sex : Main 
presenting 
complaint 
Male : Kidney 
disease 
-0.26 0.11 0.77 (0.62-0.96) 0.02 
   Male : Other unwell 0.17 0.05 1.19 (1.07-1.32) <0.01 
   Male : Pruritus 0.10 0.07 1.10 (0.96-1.26) 0.16 
   Male : Respiratory 0.06 0.08 1.06 (0.91-1.23) 0.44 
   Male : Trauma 0.48 0.06 1.62 (1.44-1.82) <0.01 
   Male : Tumour 0.15 0.10 1.16 (0.96-1.40) 0.12 
a Standard deviation 453 
b Standard error 454 
c Odds ratio 455 
d 95% Confidence interval 456 
e Lipinski et al, 2008 457 
f Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner and / or specialist status 458 




Table 6: Results from a multivariable mixed effect logistic regression model assessing the 460 
association between a range of categorical animal, owner, practitioner and practice-related 461 
factors and the probability of prescribing a systemic HPCIA in cats (n = 19,018/111,139 sick 462 
consultations). Significant (P<0.05) results are displayed in bold. 463 
Random effect Variance SD a Variable Category β SE 
b OR c (CI d) P 
Animal 0.68 0.82 Intercept England -2.79 0.21 0.06 (0.04-0.09) - 
Site 0.13 0.36  Scotland -2.74 0.24 0.07 (0.04-0.10) - 
Practice 0.44 0.66  Wales -2.55 0.24 0.08 (0.05-0.12) - 
   Categorical factors  
   Main 
presenting 
complaint 
Gastroenteric - - 1.00 - 
   Kidney disease 0.55 0.25 1.74 (1.08-2.82) 0.02 
   Other unwell 0.59 0.12 1.80 (1.43-2.26) <0.01 
   Pruritus 1.08 0.13 2.95 (2.28-3.81) <0.01 
   Respiratory 1.50 0.14 4.47 (3.41-5.85) <0.01 
   Trauma 1.06 0.12 2.89 (2.27-3.67) <0.01 
   Tumour 0.38 0.18 1.46 (1.04-2.03) 0.03 
   Sex 
 
Female - - 1.00 - 
   Male 0.12 0.03 1.13 (1.07-1.19) <0.01 
   Vaccination 
status 
Not vaccinated - - 1.00 - 
   Vaccinated -0.06 0.02 0.95 (0.91-0.98) <0.01 
   Insurance 
status 
Not insured - - 1.00 - 
   Insured -0.14 0.03 0.87 (0.83-0.92) <0.01 
   Owner urban 
status 
Urban - - 1.00 - 
   status Rural 0.05 0.03 1.05 (1.00-1.11) 0.06 
   Genetic  
breed  
group e 
West Europe - - 1.00 - 
   Asian 0.21 0.07 1.23 (1.08-1.40) <0.01 
   Crossbreed 0.14 0.04 1.16 (1.06-1.26) <0.01 
   Mediterranean 0.11 0.32 1.12 (0.59-2.11) 0.73 
   Unclassified 0.14 0.07 1.15 (1.00-1.33) 0.06 
   Unknown 0.12 0.06 1.12 (0.99-1.27) 0.07 
   Accreditation 
status 
Not accredited - - 1.00 - 
   1+ accredited site 0.10 0.22 1.10 (0.72-1.69) 0.65 
   Continuous factors  
   Age (years) Age - linear -0.23 0.03 0.80 (0.76-0.85) <0.01 
   Age - quadratic -0.13 0.02 0.88 (0.85-0.90) <0.01 
   Age - cubic 0.13 0.01 1.14 (1.11-1.17) <0.01 
   Interaction terms  
   Main 
presenting 
complaint  : 
Accreditation 
Kidney disease : accredited site 0.23 0.26 1.26 (0.76-2.08) 0.37 
   Other unwell : accredited site 0.21 0.13 1.23 (0.96-1.58) 0.10 
   Pruritus : accredited site 0.00 0.14 1.00 (0.76-1.32) 1.00 
   Respiratory : accredited site 0.23 0.15 1.26 (0.94-1.69) 0.12 
   Trauma : accredited site 0.64 0.13 1.90 (1.46-2.47) <0.01 
   Tumour : accredited site 0.19 0.19 1.21 (0.83-1.75) 0.32 
   Sex : Age 
(years) 
Male : Age - linear -0.06 0.04 0.95 (0.87-1.02) 0.17 
   Male : Age - quadratic -0.09 0.02 0.91 (0.87-0.95) <0.01 
   Male : Age - cubic 0.02 0.02 1.02 (0.98-1.06) 0.32 
a Standard deviation 464 
b Standard error 465 
c Odds ratio 466 
d 95% Confidence interval 467 




Table 7: Results from a multivariable mixed effect logistic regression model assessing the 469 
association between a range of categorical animal, owner, practitioner and practice-related 470 
factors and the probability of prescribing a topical antimicrobial in cats (n = 6,769/111,139 sick 471 
consultations). Significant (P<0.05) results are displayed in bold. 472 
Random effect Variance SD a Variable Category β SE 
b OR c (CI d) P 
Animal 0.82 0.90 Intercept England -3.98 0.17 0.02 (0.01-0.03) - 
Site 0.02 0.15  Scotland -3.94 0.19 0.02 (0.01-0.03) - 
Practice 0.03 0.16  Wales -3.91 0.19 0.02 (0.01-0.03) - 
   Categorical factors  
   Main 
presenting 
complaint 
Gastroenteric - - 1.00 - 
   Kidney disease -0.98 0.50 0.38 (0.14-1.00) 0.05 
   Other unwell 1.79 0.16 5.96 (4.37-8.12) <0.01 
   Pruritus 2.13 0.16 8.37 (6.09-11.51) <0.01 
   Respiratory 1.21 0.18 3.36 (2.35-4.82) <0.01 
   Trauma 1.34 0.17 3.82 (2.76-5.28) <0.01 
   Tumour 0.38 0.25 1.46 (0.90-2.36) 0.12 
   Sex 
 
Female - - 1.00 - 
   Male 0.05 0.03 1.05 (1.00-1.11) 0.06 
   Neutered 
status 
Not neutered - - 1.00 - 
   Neutered -0.06 0.04 0.94 (0.88-1.01) 0.09 
   Insurance 
status 
Not insured - - 1.00 - 
   Insured -0.13 0.04 0.88 (0.82-0.95) <0.01 
   Genetic 
breed  
group e 
West Europe - - 1.00 - 
   Asian -0.14 0.09 0.87 (0.73-1.03) 0.09 
   Crossbreed -0.50 0.05 0.61 (0.55-0.67) <0.01 
   Mediterranean -0.40 0.50 0.67 (0.25-1.78) 0.42 
   Unclassified -0.24 0.09 0.79 (0.66-0.95) 0.01 
   Unknown -0.43 0.08 0.65 (0.56-0.77) <0.01 
   Referral 
interest 
No - - 1.00 - 
   Yes 0.08 0.05 1.08 (0.98-1.19) 0.11 
   Continuous factors  
   Age (years) Age - linear 0.08 0.26 1.09 (0.65-1.82) 0.75 
   Age - quadratic -0.12 0.14 0.89 (0.68-1.17) 0.40 
   Age - cubic -0.14 0.14 0.87 (0.66-1.15) 0.34 
   Interaction terms  
   Main 
presenting 
complaint  : 
Age (years) 
Kidney disease : Age 1.14 0.68 3.11 (0.82-11.84) 0.10 
   Other unwell : Age -0.61 0.27 0.54 (0.32-0.91) 0.02 
   Pruritus : Age 0.18 0.27 1.19 (0.70-2.03) 0.52 
   Respiratory : Age -0.34 0.31 0.71 (0.39-1.29) 0.26 
   Trauma : Age 0.07 0.28 1.07 (0.62-1.85) 0.81 
   Tumour : Age -0.07 0.38 0.93 (0.44-1.95) 0.85 
   Kidney disease : Age - quadratic 0.52 0.32 1.69 (0.89-3.18) 0.11 
   Other unwell : Age - quadratic 0.16 0.14 1.17 (0.89-1.53) 0.26 
   Pruritus : Age - quadratic 0.42 0.14 1.52 (1.15-2.02) <0.01 
   Respiratory : Age - quadratic 0.26 0.16 1.29 (0.95-1.77) 0.11 
   Trauma : Age - quadratic 0.22 0.15 1.24 (0.93-1.65) 0.14 
   Tumour : Age - quadratic 0.16 0.20 1.18 (0.80-1.73) 0.41 
   Kidney disease : Age - cubic -0.51 0.33 0.60 (0.31-1.16) 0.13 
   Other unwell : Age - cubic 0.14 0.14 1.15 (0.87-1.52) 0.33 
   Pruritus : Age - cubic 0.04 0.15 1.04 (0.78-1.38) 0.81 
   Respiratory : Age - cubic -0.03 0.16 0.97 (0.70-1.33) 0.84 
   Trauma : Age - cubic 0.06 0.15 1.06 (0.79-1.42) 0.70 
   Tumour : Age - cubic 0.10 0.19 1.10 (0.75-1.61) 0.62 
a Standard deviation 473 
b Standard error 474 
c Odds ratio 475 
d 95% Confidence interval 476 




Figure legends 478 
Figure 1: Results from two multivariable mixed effect logistic regression models, modelling 479 
predicted probability of systemic antimicrobial prescription in sick (a) dogs and (b) cats against 480 
age of the animal at time of consultation, in years. For dogs an interaction term considering 481 
current insurance status has been included, in cats an interaction term considering sex has been 482 
included. Lines refer to predicted probability, with shading relating to 95% confidence intervals 483 
to such predictions. Points and triangles are plotted to show original data points expressing the 484 
percentage of animals of each relevant age group (rounded to 0.5-year groups) that were 485 
prescribed a systemic antimicrobial in the dataset analysed. 486 
 487 
Figure 2: Results from two multivariable mixed effect logistic regression models, modelling 488 
predicted probability of systemic highest priority critically important antimicrobial (HPCIA) 489 
prescription in sick (a) dogs and (b) cats against age of the animal at time of consultation, in 490 
years. For cats an interaction term considering sex has been included. Lines refer to predicted 491 
probability, with shading relating to 95% confidence intervals to such predictions. Points and 492 
triangles are plotted to show original data points expressing the percentage of animals of each 493 
relevant age group (rounded to 0.5-year groups) that were prescribed a systemic HPCIA in the 494 
dataset analysed. 495 
  496 
Figure 3: Results from two multivariable mixed effect logistic regression models, modelling 497 
predicted probability of topical antimicrobial prescription in sick (a) dogs and (b) cats against 498 
age of the animal at time of consultation, in years. For both species an interaction term 499 
considering main presenting complaint has been included. Lines refer to predicted probability, 500 
with shading relating to 95% confidence intervals to such predictions. Points are plotted to 501 
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Summary of antimicrobial agents authorised for use in dogs and/or cats in the United Kingdom. Information 
source: Veterinary Medicines Directorate (https://www.vmd.defra.gov.uk/ProductInformationDatabase/), 
accessed 1 April 2016. 
 
Antimicrobial class Antimicrobial agent 








Clavulanic acid potentiated amoxicillin Amoxicillin-clavulanic acid 
Cloxacillin Cloxacillin 
1st generation cephalosporin Cefalexin 
3rd generation cephalosporin Cefovecin 
Penicillin Benzathine benzyl penicillin 










Potentiated sulphonamide Sulfadiazine-trimethoprim 








Descriptive demographic summary of sick canine and feline consultations utilised for analyses of factors 
associated with antimicrobial prescription, focusing on the percentage of consultations contributed by a range 
of genetically similar breed groups, as defined by Vonholdt et al. (2010) for dog breeds, and Lipinski et al. 
(2008) for cat breeds. 
Breeds % of consults (CI a) Breeds % of consults (CI a) 
Dog breed group Cat breed group 
Ancient / spitz 1.3 (1.2-1.4) Asian 3.5 (3.3-3.8) 
Crossbreed 22.1 (21.4-22.8) Crossbreed 87.6 (86.3-88.8) 
Herding 4.7 (4.4-5.1) Mediterranean 0.1 (0.1-0.1) 
Mastiff-like 9.5 (9.1-9.9) West Europe 6.4 (5.3-7.5) 
Retriever 14.5 (13.8-15.2) Unclassified 2.5 (2.3-2.7) 
Scent hound 2.6 (2.5-2.8) Unknown / missing 4.0 (3.1-4.8) 
Sight hound 1.6 (1.5-1.8)   
Small terriers 12.8 (12.4-13.2)   
Spaniel 13.7 (13.3-14.1)   
Toy 4.7 (4.4-5.0)   
Working dog 5.2 (5.0-5.4)   
Unclassified 11.3 (10.9-11.6)   
Unknown  / missing 1.2 (1.0-1.4)   






Descriptive summary of the percentage of total sick canine consultations where an animal was prescribed at 
least one antimicrobial (systemic, topical or systemic highest priority critically important (HPCIA) compared 




                                               
Dog breed 
 Systemic Topical Systemic HPCIA 
d n consults % b 95% CI c % 95% CI % 95% CI 
Crossbreed Crossbreed 59,010 24.9 23.9-25.8 13.3 12.9-13.7 1.2 0.9-1.4 
Herding Border collie 9,821 26.7 25.2-28.2 8.1 7.5-8.7 1.0 0.6-1.5 
Border terrier 5,225 24.3 22.6-26.1 16.0 14.7-17.3 1.4 0.9-1.8 
Mastiff-like Boxer 4,780 22.6 21.0-24.2 17.7 16.4-19.1 0.7 0.4-0.9 
Bulldog 2,530 32.7 30.5-34.9 23.3 21.3-25.3 1.1 0.6-1.6 
Staffordshire bull terrier 9,719 24.8 23.6-26.0 15.6 14.8-16.5 0.7 0.5-1.0 
Retriever Golden retriever 6,223 26.3 24.4-28.1 15.1 13.9-16.4 1.0 0.7-1.4 
Labrador retriever 30,977 22.7 21.6-23.8 15.2 14.5-15.9 1.0 0.7-1.2 
Scent hound Dachshund 3,065 25.1 22.7-27.4 9.6 8.4-10.9 2.7 1.8-3.5 
Small terrier Jack russell terrier 14,869 26.1 24.9-27.4 16.7 15.8-17.7 1.4 1.1-1.8 
West highland white terrier 11,040 28.9 27.5-30.3 10.8 10.0-11.7 2.9 2.4-3.5 
Yorkshire terrier 6,328 27.6 25.9-29.2 11.0 10.4-11.6 3.2 2.6-3.8 
Spaniel Cavalier King Charles 
spaniel 
7,586 22.5 21.1-24.0 14.0 13.1-14.9 1.3 0.9-1.7 
Cock r spaniel 15,312 27.8 26.5-29.2 18.1 17.2-18.9 1.7 1.4-2.1 
English springer spaniel 6,774 26.3 24.8-27.9 14.1 13.1-15.2 1.3 0.9-1.7 
Springer spaniel 4,073 27.4 25.6-29.2 15.5 14.1-16.8 1.4 0.9-1.9 
Toy Chihuahua 2,583 26.5 24.3-28.8 7.9 6.8-9.0 2.3 1.5-3.1 
Pug 2,679 24.7 22.6-26.7 21.5 19.9-23.1 1.8 1.1-2.4 
Shih tzu 5,938 23.4 21.8-25.0 17.3 16.2-18.5 2.0 1.6-2.5 
Unclassified Bichon frise 3,314 25.8 24.2-27.4 18.7 17.1-20.4 1.4 0.9-1.8 
Lhasa apso 3,060 26.5 24.3-28.7 17.3 15.5-19.1 2.4 1.7-3.1 
Unknown Unknown 3,182 24.3 22.5-26.1 12.1 10.8-13.3 0.9 0.5-1.3 
Working dog German shepherd dog 6,695 28.4 27.0-29.8 13.5 12.5-14.4 1.1 0.7-1.6 
Schnauzer 3,376 27.2 25.2-29.1 12.3 11.0-13.5 1.2 0.7-1.8 
a Vonholdt et al., 2010 
b Percentage of consultations where at least one antimicrobial was prescribed 
c 95% Confidence Interval 





Descriptive summary of the percentage of total sick canine consultations prescribed a systemic antimicrobial. 
Also included are parameter estimates from a series of univariable mixed effect logistic regression models 
assessing the association between a range of animal, owner, practitioner and practice-related factors and the 
probability of prescribing a systemic antimicrobial. Random effects include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE b OR c CI P 
Categorical factors 
Country England (Intercept) 25.7 (24.7-26.7) -1.16 0.03 0.31 0.30-0.33  
Scotland 26.8 (24.9-28.7) 0.04 0.05 1.04 0.94-1.16 0.45 
Wales 24.7 (22.3-27.1) -0.02 0.07 0.98 0.86-1.12 0.76 
Main presenting complaint Gastroenteric (Intercept) 40.2 (41.0-44.8) -0.46 0.03 0.63 0.59-0.67  
Other unwell 22.0 (21.3-22.8) -0.93 0.02 0.34 0.38-0.41 <0.01 
Kidney disease 30.1 (27.4-32.8) -0.39 0.06 0.68 0.61-0.76 <0.01 
Pruritus 27.0 (25.7-28.4) -0.65 0.02 0.52 0.51-0.54 <0.01 
Respiratory 42.9 (41.0-44.8) 0.11 0.03 1.12 1.06-1.17 <0.01 
Trauma 22.5 (21.5-23.6) -0.86 0.02 0.42 0.41-0.44 <0.01 
Tumour 18.4 (17.5-19.3) -1.17 0.03 0.31 0.30-0.33 <0.01 
Sex Female (Intercept) 25.9 (24.9-26.8) -1.15 0.03 0.32 0.30-0.33  
Male 25.6 (24.7-26.4) -0.01 0.01 0.99 0.97-1.01 0.19 
Neuter 
status 
Un-neutered (Intercept) 27.4 (26.5-28.2) -1.08 0.03 0.34 0.32-0.36  
Neutered 24.8 (24.0-25.7) -0.12 0.01 0.89 0.87-0.91 <0.01 
Microchip status Un-microchipped (Intercept) 26.4 (25.5-27.3) -1.14 0.03 0.32 0.30-0.34  
Microchipped 25.2 (24.3-26.1) -0.03 0.01 0.97 0.95-0.99 0.01 
Vaccination status Un-vaccinated (Intercept) 27.3 (26.4-28.2) -1.10 0.03 0.33 0.32-0.35  
Vaccinated 25.1 (24.2-26.0) -0.09 0.01 0.92 0.90-0.94 <0.01 
Insurance status Un-insured (Intercept) 26.7 (25.9-27.6) -1.11 0.03 0.33 0.31-0.35  
Insured 23.7 (22.7-24.7) -0.14 0.01 0.87 0.85-0.89 <0.01 
Owner urban status Urban (Intercept) 25.5 (24.5-26.4) -1.16 0.03 0.31 0.30-0.33  
Rural 26.2 (25.0-27.3) 0.01 0.01 1.01 0.98-1.03 0.71 
Genetic breed group d Retriever (Intercept) 23.4 (22.3-24.5) -1.28 0.03 0.28 0.26-0.29  
Crossbreed  24.9 (23.9-25.8) 0.08 0.02 1.08 1.05-1.12 <0.01 
Ancient / spitz 28.8 (26.7-30.8) 0.27 0.05 1.32 1.20-1.44 <0.01 
Herding 26.5 (25.2-27.8) 0.14 0.03 1.15 1.09-1.22 <0.01 
Mastiff-like 26.2 (25.2-27.1) 0.16 0.02 1.17 1.12-1.22 <0.01 
Scent hound 25.6 (24.0-27.1) 0.13 0.04 1.13 1.06-1.21 <0.01 
Sight hound 29.5 (27.6-31.5) 0.30 0.04 1.35 1.25-1.47 <0.01 
Small terrier 27.3 (26.2-28.4) 0.20 0.02 1.22 1.17-1.27 <0.01 
Spaniel 26.5 (25.4-27.5) 0.16 0.02 1.17 1.13-1.22 <0.01 
Toy 24.7 (23.4-25.9) 0.06 0.03 1.06 1.01-1.12 0.03 
Unclassified 26.0 (25.0-27.0) 0.13 0.02 1.14 1.09-1.19 <0.01 
Unknown 24.3 (22.6-26.1) 0.12 0.05 1.13 1.03-1.24 0.01 
Working dog 27.4 (26.4-28.4) 0.21 0.03 1.24 1.18-1.30 <0.01 
Practice type Small animal (Intercept) 25.4 (24.3-26.4) -1.19 0.03 0.31 0.29-0.32  
Mixed 26.6 (25.0-28.3) 0.16 0.07 1.18 1.03-1.34 0.02 
Small & equine 23.1 (20.2-25.9) -0.04 0.15 0.96 0.71-1.30 0.79 
Small & large 28.7 (26.2-31.2) 0.16 0.14 1.17 0.89-1.55 0.27 
Accreditation Not accredited (Intercept) 28.4 (26.3-30.5) -0.93 0.07 0.40 0.35-0.46  
1+ accredited site 25.2 (24.3-26.1) -0.27 0.07 0.77 0.66-0.89 <0.01 
Hospital status No hospital site (Intercept) 26.2 (25.2-27.2) -1.14 0.03 0.32 0.30-0.34  
1+ hospital site 23.9 (22.7-25.1) -0.09 0.06 0.91 0.81-1.04 0.16 
Referral interest No (Intercept) 26.0 (25.1-26.9) -1.12 0.03 0.33 0.31-0.35  
Yes 25.1 (23.2-26.9) -0.11 0.05 0.89 0.80-0.99 0.04 
Employed RCVS AVP e None (Intercept) 26.3 (25.3-27.2) -1.13 0.03 0.32 0.31-0.34  
1+ AVP 24.0 (22.2-25.8) -0.14 0.06 0.87 0.77-0.98 0.02 
Employed RCVS specialist 
e 
None (Intercept) 25.8 (25.0-26.7) -1.15 0.03 0.32 0.30-0.33  
1+ specialist 22.0 (19.1-24.8) -0.18 0.15 0.84 0.63-1.11 0.21 
Continuous factors 
Age (years) Intercept  -1.14 0.03 0.32 0.31-0.34  
Age - linear  -0.10 0.01 0.90 0.88-0.92 <0.01 
Age - quadratic  -0.03 0.01 0.97 0.96-0.99 <0.01 
Age - cubic  0.02 0.01 1.02 1.02-1.03 <0.01 
rIMD f Intercept  -1.16 0.03 0.31 0.30-0.33  
rIMD  -0.02 0.01 0.98 0.97-1.00 0.04 
Dogs per household g Intercept  -1.16 0.03 0.31 0.30-0.33  
Dogs per household  -0.01 0.01 0.99 0.98-1.01 0.24 
Dogs per km2 g Intercept  -1.16 0.03 0.31 0.30-0.33  
Dogs per km  -0.01 0.01 1.00 0.98-1.01 0.34 
a 95% Confidence Interval 
b Standard Error 




d Vonholdt et al., 2010 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 
f Rescaled Indices of Multiple Deprivation (rIMD) quintile, 1 = most deprived 





Descriptive summary of the percentage of total sick canine consultations prescribed a systemic highest priority 
critically important antimicrobial (HPCIA). Also included are parameter estimates from a series of univariable 
mixed effect logistic regression models assessing the association between a range of animal, owner, 
practitioner and practice-related factors and the probability of prescribing a systemic HPCIA. Random effects 
include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE b OR c CI P 
Categorical factors 
Country England (Intercept) 1.4 (1.2-1.7) -4.80 0.07 0.01 0.01-0.01 1 
Scotland 1.4 (0.9-1.8) -0.15 0.19 0.86 0.59-1.24 0.42 
Wales 1.1 (0.7-1.6) -0.11 0.20 0.90 0.61-1.32 0.59 
Main presenting complaint Gastroenteric (Intercept) 1.7 (0.8-2.7) -4.54 0.08 0.01 0.01-0.01  
Kidney disease  2.2 (1.5-2.8) 0.31 0.18 1.36 0.95-1.95 0.09 
Other unwell 1.5 (1.3-1.8) -0.21 0.06 0.81 0.73-0.91 <0.01 
Pruritus 1.6 (1.3-1.8) -0.18 0.07 0.84 0.74-0.95 <0.01 
Respiratory 2.8 (2.4-3.3) 0.44 0.08 1.55 1.31-1.82 <0.01 
Trauma 0.5 (0.4-0.7) -1.13 0.08 0.32 0.27-0.38 <0.01 
Tumour 0.8 (0.6-1.0) -0.80 0.11 0.45 0.37-0.56 <0.01 
Sex Female (Intercept) 1.4 (1.2-1.7) -4.80 0.07 0.01 0.01-0.01  
Male 1.4 (1.2-1.6) -0.03 0.04 0.97 0.90-1.05 0.47 
Neuter status Un-neutered (Intercept) 1.4 (1.2-1.6) -4.82 0.07 0.01 0.01-0.01  
Neutered 1.4 (1.2-1.7) 0.00 0.04 1.00 0.92-1.09 0.94 
Microchip status Un-microchipped (Intercept) 1.5 (1.3-1.7) -4.75 0.07 0.01 0.01-0.01  
Microchipped 1.4 (1.1-1.6) -0.12 0.04 0.88 0.82-0.96 <0.01 
Vaccination status Un-vaccinated (Intercept) 1.5 (1.3-1.7) -4.73 0.07 0.01 0.01-0.01  
Vaccinated 1.4 (1.2-1.6) -0.13 0.04 0.88 0.81-0.96 <0.01 
Insurance status Un-insured (Intercept) 1.3 (1.1-1.6) -4.86 0.07 0.01 0.01-0.01  
Insured 1.5 (1.3-1.8) 0.13 0.04 1.13 1.04-1.23 <0.01 
Owner urban status Urban (Intercept) 1.3 (1.1-1.5) -4.83 0.07 0.01 0.01-0.01  
Rural 1.6 (1.3-2.0) 0.03 0.05 1.04 0.95-1.14 0.49 
Genetic breed group d Retriever (Intercept) 1.0 (0.7-1.2) -5.19 0.09 0.01 0.01-0.01  
Crossbreed  1.2 (0.9-1.4) 0.06 0.22 1.07 0.69-1.64 0.78 
Ancient / spitz 0.9 (0.5-1.3) 0.24 0.08 1.27 1.09-1.47 <0.01 
Herding 1.2 (0.7-1.6) 0.08 0.12 1.09 0.86-1.37 0.50 
Mastiff-like 1.0 (0.8-1.1) 0.09 0.10 1.09 0.90-1.33 0.37 
Scent hound 1.9 (1.4-2.4) 0.67 0.13 1.95 1.52-2.51 <0.01 
Sight hound 1.4 (0.9-1.8) 0.34 0.17 1.41 1.01-1.97 0.04 
Small terrier 2.3 (1.9-2.6) 0.80 0.08 2.23 1.91-2.61 <0.01 
Spaniel 1.5 (1.3-1.8) 0.45 0.08 1.58 1.34-1.80 <0.01 
Toy 2.2 (1.8-2.6) 0.90 0.10 2.45 2.02-2.99 <0.01 
Unclassified 1.5 (1.2-1.8) 0.43 0.09 1.53 1.29-1.81 <0.01 
Unknown 0.9 (0.5-1.3) 0.18 0.22 1.20 0.77-1.85 0.43 
Working dog 1.4 (1.1-1.8) 0.45 0.11 1.57 1.27-1.93 <0.01 
Practice type Small animal (Intercept) 1.3 (1.1-1.5) -4.85 0.07 0.01 0.01-0.01  
Mixed 1.7 (1.0-2.3) 0.18 0.17 1.20 0.86-1.66 0.29 
Small & equine 1.2 (0.7-1.6) -0.10 0.40 0.91 0.42-1.98 0.80 
Small & large 1.5 (1.0-1.9) 0.08 0.35 1.09 0.55-2.15 0.81 
Accreditation Not accredited (Intercept) 1.7 (1.1-2.4) -4.65 0.18 0.01 0.01-0.01  
1+ accredited site 1.4 (1.1-1.6) -0.19 0.19 0.83 0.57-1.20 0.33 
Hospital status No hospital site (Intercept) 1.5 (1.3-1.8) -4.78 0.07 0.01 0.01-0.01  
1+ hospital site 1.0 (0.9-1.1) -0.17 0.16 0.84 0.62-1.15 0.28 
Referral interest No (Intercept) 1.5 (1.2-1.7) -4.80 0.08 0.01 0.01-0.01  
Yes 1.2 (1.0-1.5) -0.06 0.14 0.94 0.72-1.23 0.66 
Employed RCVS AVP e None (Intercept) 1.5 (1.2-1.7) -4.79 0.07 0.01 0.01-0.01  
1+ AVP 1.3 (1.0-1.5) -0.13 0.16 0.87 0.64-1.19 0.39 
Employed RCVS specialist 
e 
None (Intercept) 1.4 (1.2-1.6) -4.81 0.06 0.01 0.01-0.01  
1+ specialist 0.8 (0.5-1.1) -0.26 0.38 0.77 0.37-1.62 0.49 
Continuous factors 
Age (years) Intercept  -4.81 0.07 0.01 0.01-0.01  
Age - linear  0.20 0.04 1.22 1.13-1.32 <0.01 
Age - quadratic  -0.03 0.03 0.97 0.93-1.02 0.23 
Age - cubic  0.04 0.02 1.04 1.01-1.08 0.01 
rIMD f Intercept  -4.82 0.06 0.01 0.01-0.01  
rIMD  0.02 0.02 1.02 0.97-1.07 0.39 
Dogs per household g Intercept  -4.82 0.06 0.01 0.01-0.01  
Dogs per household  0.02 0.03 1.03 0.97-1.09 0.40 
Dogs per km2 g Intercept  -4.82 0.06 0.01 0.01-0.01  
Dogs per km  -0.02 0.02 0.98 0.94-1.02 0.31 
a 95% Confidence Interval 




c Odds Ratio 
d Vonholdt et al., 2010 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 
f Rescaled Indices of Multiple Deprivation (rIMD) quintile, 1 = most deprived 





Descriptive summary of the percentage of total sick canine consultations prescribed a topical antimicrobial. 
Also included are parameter estimates from a series of univariable mixed effect logistic regression models 
assessing the association between a range of animal, owner, practitioner and practice-related factors and the 
probability of prescribing a topical antimicrobial. Random effects include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE b OR c CI P 
Categorical factors 
Country England (Intercept) 14.1 (13.9-14.6) -1.82 0.02 0.16 0.16-0.17  
Scotland 13.4 (11.9-14.9) 0.03 0.05 1.03 0.93-1.13 0.58 
Wales 14.7 (13.9-15.6) -0.06 0.06 0.95 0.85-1.06 0.34 
Main presenting complaint Gastroenteric (Intercept) 1.8 (1.2-2.5) -3.99 0.05 0.02 0.02-0.02  
Kidney disease  3.2 (2.4-4.1) 0.61 0.14 1.84 1.41-2.41 <0.01 
Other unwell 15.5 (15.0-16.0) 2.28 0.04 9.79 8.99-10.65 <0.01 
Pruritus 31.7 (30.7-32.8) 3.23 0.04 25.30 23.23-27.55 <0.01 
Respiratory 2.9 (2.3-3.6) 0.48 0.07 1.61 1.40-1.85 <0.01 
Trauma 6.6 (6.2-7.0) 1.32 0.05 3.75 3.43-4.11 <0.01 
Tumour 5.9 (5.5-6.4) 1.22 0.05 3.38 3.04-3.76 <0.01 
Sex Female (Intercept) 13.6 (13.3-14.0) -1.87 0.02 0.15 0.15-0.16  
Male 14.8 (14.4-15.2) 0.10 0.01 1.11 1.08-1.13 <0.01 
Neuter status Un-neutered (Intercept) 15.0 (14.6-15.4) -1.76 0.02 0.17 0.17-0.18  
Neutered 13.8 (13.4-14.2) -0.10 0.01 0.91 0.88-0.93 <0.01 
Microchip status Un-microchipped (Intercept) 13.4 (13.1-13.8) -1.89 0.02 0.15 0.15-0.16  
Microchipped 14.9 (14.5-15.3) 0.13 0.01 1.14 1.11-1.16 <0.01 
Vaccination status Un-vaccinated (Intercept) 13.2 (12.9-13.6) -1.90 0.02 0.15 0.14-0.16  
Vaccinated 14.6 (14.3-15.0) 0.11 0.01 1.12 1.09-1.15 <0.01 
Insurance status Un-insured (Intercept) 14.5 (14.2-14.9) -1.80 0.02 0.17 0.16-0.17  
Insured 13.6 (13.2-14.1) -0.07 0.01 0.93 0.91-0.96 <0.01 
Owner urban status Urban (Intercept) 14.4 (14.0-14.8) -1.81 0.02 0.16 0.16-0.17  
Rural 14.0 (13.6-14.4) -0.04 0.02 0.97 0.94-1.00 0.02 
Genetic breed group d Retriever (Intercept) 15.3 (14.7-16.0) -1.72 0.02 0.18 0.17-0.19  
Crossbreed  13.3 (12.9-13.7) -0.01 0.06 0.99 0.89-1.11 0.92 
Ancient / spitz 15.0 (13.5-16.5) -0.16 0.02 0.85 0.82-0.89 <0.01 
Herding 8.2 (7.7-8.7) -0.70 0.04 0.50 0.46-0.54 <0.01 
Mastiff-like 17.0 (16.4-17.6) 0.11 0.03 1.11 1.06-1.17 <0.01 
Scent hound 13.3 (12.2-14.3) -0.18 0.04 0.83 0.77-0.91 <0.01 
Sight hound 5.3 (4.4-6.2) -1.17 0.07 0.31 0.27-0.36 <0.01 
Small terrier 12.8 (12.3-13.3) -0.22 0.02 0.80 0.76-0.84 <0.01 
Spaniel 16.1 (15.5-16.6) 0.04 0.02 1.04 0.99-1.08 0.13 
Toy 15.5 (14.7-16.3) -0.02 0.03 0.99 0.92-1.05 0.64 
Unclassified 15.5 (14.9-16.1) 0.01 0.02 1.01 0.96-1.06 0.73 
Unknown 12.1 (10.8-13.4) -0.29 0.06 0.75 0.66-0.85 <0.01 
Working dog 13.7 (12.9-14.5) -0.13 0.03 0.88 0.82-0.93 <0.01 
Practice type Small animal (Intercept) 14.3 (13.9-14.8) -1.81 0.02 0.16 0.16-0.17  
Mixed 13.6 (12.9-14.3) -0.08 0.04 0.92 0.85-1.00 0.05 
Small & equine 16.2 (14.3-18.2) 0.17 0.09 1.19 0.99-1.42 0.06 
Small & large 14.5 (13.6-15.4) 0.00 0.09 1.00 0.84-1.2 0.99 
Accreditation Not accredited (Intercept) 13.3 (12.3-14.4) -1.90 0.05 0.15 0.14-0.16  
1+ accredited site 14.4 (14.0-14.7) 0.09 0.05 1.10 1.00-1.20 0.05 
Hospital status No hospital site (Intercept) 14.0 (13.6-14.4) -1.83 0.02 0.16 0.15-0.17  
1+ hospital site 15.0 (14.3-15.7) 0.07 0.04 1.07 0.99-1.15 0.09 
Referral interest No (Intercept) 14.2 (13.9-14.6) -1.83 0.02 0.16 0.16-0.17  
Yes 14.2 (13.5-15.0) 0.03 0.03 1.03 0.96-1.1.0 0.47 
Employed RCVS AVP e None (Intercept) 13.9 (13.5-14.3) -1.84 0.02 0.16 0.15-0.17  
1+ AVP 15.3 (14.6-15.9) 0.08 0.04 1.08 1.01-1.16 0.03 
Employed RCVS specialist 
e 
None (Intercept) 14.3 (13.9-14.6) -1.82 0.02 0.16 0.16-0.17  
1+ specialist 12.0 (10.2-13.7) -0.18 0.09 0.84 0.70-1.00+ 0.05 
Continuous factors 
Age (years) Intercept  -1.74 0.02 0.20 0.17-0.18  
Age - linear  -0.32 0.01 0.73 0.71-0.75 <0.01 
Age - quadratic  -0.12 0.01 0.89 0.88-0.90 <0.01 
Age - cubic  0.03 0.01 1.03 1.02-1.04 <0.01 
rIMD f Intercept  -1.82 0.02 0.16 0.16-0.17 <0.01 
rIMD  0.01 0.01 1.01 0.99-1.02 0.32 
Dogs per household g Intercept  -1.82 0.02 0.16 0.16-0.17  
Dogs per household  -0.01 0.01 0.99 0.98-1.01 0.40 
Dogs per km2 g Intercept  -1.82 0.02 0.16 0.16-0.17  
Dogs per km  0.00 0.01 1.00 0.99-1.01 0.98 
a 95% Confidence Interval 
b Standard Error 




d Vonholdt et al., 2010 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 
f Rescaled Indices of Multiple Deprivation (rIMD) quintile, 1 = most deprived 





Descriptive summary of the percentage of total sick feline consultations where an animal was prescribed at 
least one antimicrobial (systemic, topical or systemic highest priority critically important (HPCIA) compared 




                 
Cat breed 
 Systemic Topical Systemic HPCIA 
d n consults % b 95% CI c % 95% CI % 95% CI 
Asian Burmese 1,314 32.1 28.8-35.4 8.9 6.8-11.0 18.8 15.6-22.0 
Asian Siamese 1,814 35.3 31.9-38.7 5.0 3.9-6.2 17.6 14.8-20.4 
Crossbreed Crossbreed 93,599 32.9 31.9-33.8 5.7 5.5-5.9 17.2 16.1-18.4 
Unclassified Bengal 1,024 37.0 33.1-40.9 8.8 6.7-11.0 20.3 16.8-23.8 
Unknown Unknown 4,244 34.0 32.4-35.6 7.4 6.5-8.3 18.0 15.6-20.3 
West Europe British 2,707 29.1 26.1-32.2 9.5 7.3-11.6 14.6 12.2-17.0 
West Europe Persian 1,870 29.9 26.6-33.2 11.0 9.3-12.7 16.1 13.4-18.8 
a Lipinski et al., 2008 
b Percentage of consultations where at least one antimicrobial was prescribed 
c 95% Confidence Interval 





Descriptive summary of the percentage of total sick feline consultations prescribed a systemic antimicrobial. 
Also included are parameter estimates from a series of univariable mixed effect logistic regression models 
assessing the association between a range of animal, owner, practitioner and practice-related factors and the 
probability of prescribing a systemic antimicrobial. Random effects include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE b OR c CI P 
Categorical factors 
Country England (Intercept) 32.5 (31.5-33.5) -0.77 0.03 0.46 0.44-0.49  
Scotland 37.0 (33.9-40.1) 0.06 0.09 1.06 0.90-1.26 0.47 
Wales 33.4 (29.9-37.0) 0.34 0.10 1.40 1.15-1.71 <0.01 
Main presenting complaint Gastroenteric (Intercept) 30.5 (28.1-32.9) -0.83 0.04 0.44 0.41-0.47  
Kidney disease 20.7 (18.8-22.6) -0.47 0.05 0.62 0.56-0.69 <0.01 
Other unwell 27.2 (26.1-28.2) -0.20 0.03 0.82 0.78-0.87 <0.01 
Pruritus 26.8 (24.9-28.7) -0.23 0.03 0.79 0.74-0.85 <0.01 
Respiratory 53.0 (50.6-55.4) 0.91 0.04 2.49 2.32-2.69 <0.01 
Trauma 53.5 (52.3-54.7) 0.99 0.03 2.68 2.53-2.84 <0.01 
Tumour 20.7 (19.0-22.3) -0.58 0.05 0.56 0.51-0.62 <0.01 
Sex Female (Intercept) 30.1 (29.1-31.1) -0.88 0.03 0.42 0.39-0.44  
Male 35.4 (34.4-36.4) 0.26 0.02 1.30 1.26-1.34 <0.01 
Neuter 
status 
Un-neutered (Intercept) 33.1 (31.9-34.2) -0.74 0.03 0.48 0.45-0.51  
Neutered 32.8 (31.8-33.8) -0.00 0.02 1.00 0.96-1.04 0.87 
Microchip status Un-microchipped (Intercept) 32.2 (31.3-33.2) -0.80 0.03 0.45 0.43-0.48  
Microchipped 33.9 (32.8-35.1) 0.14 0.02 1.15 1.12-1.19 <0.01 
Vaccination status Un-vaccinated (Intercept) 33.6 (32.6-34.6) -0.73 0.03 0.48 0.46-0.51  
Vaccinated 32.2 (31.2-33.2) -0.03 0.02 0.97 0.94-1.00 0.05 
Insurance status Un-insured (Intercept) 33.8 (32.8-34.8) -0.71 0.03 0.49 0.47-0.52  
Insured 28.9 (27.7-30.1) -0.20 0.02 0.82 0.79-0.86 <0.01 
Owner urban status Urban (Intercept) 32.1 (31.1-33.1) -0.76 0.03 0.47 0.44-0.50  
Rural 34.8 (33.3-36.2) 0.04 0.02 1.05 1.00-1.09 0.04 
Genetic breed group d West Europe (Intercept) 30.8 (29.1-32.4) -0.88 0.04 0.41 0.38-0.45  
Asian 33.1 (30.7-35.5) 0.14 0.05 1.15 1.04-1.27 0.01 
Crossbreed 32.9 (31.9-33.8) 0.14 0.03 1.16 1.0-1.23 <0.01 
Mediterranean 42.5 (27.5-57.4) 0.48 0.26 1.61 0.97-2.67 0.06 
Unclassified 34.7 (32.2-37.3) 0.22 0.06 1.25 1.11-1.39 <0.01 
Unknown 34.0 (32.4-35.6) 0.18 0.05 1.19 1.08-1.31 <0.01 
Practice type Small animal (Intercept) 32.2 (31.1-33.2) -0.79 0.03 0.45 0.43-0.48  
Mixed 35.4 (32.8-38.0) 0.24 0.08 1.27 1.10-1.47 <0.01 
Small & equine 28.7 (22.4-35.0) -0.02 0.17 0.98 0.70-1.38 0.90 
Small & large 37.7 (32.7-42.7) 0.25 0.16 1.29 0.94-1.76 0.11 
Accreditation Not accredited (Intercept) 36.4 (34.2-38.6) -0.54 0.08 0.58 0.50-0.68  
1+ accredited site 32.2 (31.2-33.2) -0.23 0.09 0.80 0.67-0.94 <0.01 
Hospital status No hospital site (Intercept) 33.3 (32.2-34.4) -0.72 0.03 0.49 0.46-0.52  
1+ hospital site 31.2 (29.5-32.9) -0.13 0.07 0.88 0.76-1.01 0.07 
Referral interest No (Intercept) 33.2 (32.1-34.3) -0.71 0.03 0.49 0.46-0.53  
Yes 31.9 (30.1-33.8) -0.11 0.06 0.90 0.79-1.01 0.08 
Employed RCVS AVP e None (Intercept) 33.4 (32.3-34.5) -0.71 0.03 0.49 0.46-0.53  
1+ AVP 31.3 (29.4-33.2) -0.18 0.07 0.84 0.73-0.96 0.01 
Employed RCVS specialist 
e 
None (Intercept) 32.9 (32.0-33.9) -0.74 0.03 0.48 0.45-0.51  
1+ specialist 29.0 (24.7-33.4) -0.14 0.17 0.87 0.62-1.21 0.41 
Continuous factors 
Age (years) Intercept  -0.64 0.03 0.53 0.50-0.56  
Age - linear  -0.53 0.02 0.59 0.57-0.61 <0.01 
Age - quadratic  -0.13 0.01 0.87 0.86-0.89 <0.01 
Age - cubic  0.12 0.01 1.13 1.11-1.15 <0.01 
rIMD f Intercept  -0.74 0.03 0.48 0.45-0.50  
IMD  -0.03 0.01 0.97 0.96-0.99 <0.01 
Cats per household g Intercept  -0.74 0.03 0.48 0.45-0.50  
Cats per household  -0.00 0.01 1.00 0.97-1.02 0.73 
Cats per km2 g Intercept  -0.74 0.03 0.48 0.45-0.50  
Cats per km  -0.02 0.01 0.98 0.97-1.00 0.02 
a 95% Confidence Interval 
b Standard Error 
c Odds Ratio 
d Lipinski et al., 2008 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 
f Rescaled Indices of Multiple Deprivation (rIMD) quintile, 1 = most deprived 





Descriptive summary of the percentage of total sick feline consultations prescribed a systemic highest priority 
critically important antimicrobial (HPCIA). Also included are parameter estimates from a series of univariable 
mixed effect logistic regression models assessing the association between a range of animal, owner, 
practitioner and practice-related factors and the probability of prescribing a systemic HPCIA. Random effects 
include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE b OR c CI P 
 Categorical factors 
Country England (Intercept) 17.1 (16.0-18.1) -1.71 0.06 0.18 0.16-0.20  
Scotland 17.5 (9.8-25.3) 0.07 0.12 1.07 0.86-1.35 0.54 
Wales 18.0 (14.9-21.1) 0.18 0.17 1.20 0.86-1.68 0.29 
Main presenting complaint Gastroenteric (Intercept) 6.9 (5.9-7.9) -2.71 0.07 0.07 0.06-0.08  
Kidney disease 13.7 (11.9-15.5) 0.75 0.07 2.12 1.84-2.44 <0.01 
Other unwell 14.2 (13.2-15.2) 0.79 0.05 2.20 2.02-2.41 <0.01 
Pruritus 19.8 (18.1-21.5) 1.17 0.05 3.23 2.92-3.57 <0.01 
Respiratory 29.4 (26.9-31.9) 1.72 0.05 5.57 5.00-6.19 <0.01 
Trauma 27.1 (24.6-29.5) 1.68 0.05 5.35 4.88-5.87 <0.01 
Tumour 12.3 (11.0-13.7) 0.57 0.07 1.77 1.55-2.01 <0.01 
Sex Female (Intercept) 16.3 (15.2-17.4) -1.76 0.06 0.17 0.15-0.19  
Male 17.9 (16.7-19.1) 0.13 0.02 1.14 1.10-1.18 <0.01 
Neuter 
status 
Un-neutered (Intercept) 16.3 (15.0-17.7) -1.78 0.06 0.17 0.15-0.19  
Neutered 17.3 (16.2-18.4) 0.10 0.03 1.11 1.06-1.16 <0.01 
Microchip status Un-microchipped (Intercept) 16.8 (15.7-17.9) -1.73 0.06 0.18 0.16-0.20  
Microchipped 17.6 (16.4-18.8) 0.08 0.02 1.09 1.05-1.13 <0.01 
Vaccination status Un-vaccinated (Intercept) 17.5 (16.3-18.7) -1.67 0.06 0.19 0.17-0.21  
Vaccinated 16.8 (15.7-17.8) -0.05 0.02 0.95 0.91-0.98 <0.01 
Insurance status Un-insured (Intercept) 17.6 (16.5-18.8) -1.67 0.06 0.19 0.17-0.21  
Insured 15.0 (13.7-16.2) -0.13 0.03 0.88 0.84-0.93 <0.01 
Owner urban status Urban (Intercept) 16.5 (15.4-17.6) -1.71 0.06 0.18 0.16-0.20  
Rural 18.7 (16.9-20.5) 0.06 0.03 1.06 1.01-1.11 0.03 
Genetic breed group d West Europe (Intercept) 15.3 (13.8-16.9) -1.88 0.07 0.15 0.13-0.17  
Asian 17.2 (15.2-19.3) 0.19 0.07 1.21 1.06-1.37 <0.01 
Crossbreed 17.2 (16.1-18.3) 0.20 0.04 1.23 1.13-1.33 <0.01 
Mediterranean 22.0 (7.1-36.9) 0.11 0.32 1.12 0.60-2.09 0.73 
Unclassified 16.6 (14.7-18.6) 0.15 0.07 1.16 1.01-1.34 0.04 
Unknown 18.0 (15.6-20.3) 0.14 0.06 1.15 1.02-1.30 0.02 
Practice type Small animal (Intercept) 16.5 (15.3-17.8) -1.73 0.06 0.18 0.16-0.20  
Mixed 18.8 (16.1-21.5) 0.10 0.16 1.11 0.81-1.50 0.52 
Small & equine 18.2 (12.7-23.7) 0.27 0.37 1.30 0.64-2.67 0.47 
Small & large 20.1 (14.4-25.9) 0.28 0.32 1.32 0.71-2.46 0.38 
Accreditation Not accredited (Intercept) 14.5 (10.5-18.4) -1.93 0.16 0.15 0.11-0.20  
1+ accredited site 17.7 (16.6-18.7) 0.27 0.17 1.31 0.93-1.83 0.12 
Hospital status No hospital site (Intercept) 17.0 (15.7-18.4) -1.67 0.06 0.19 0.17-0.21  
1+ hospital site 17.4 (15.6-19.1) -0.14 0.15 0.87 0.65-1.16 0.34 
Referral interest No (Intercept) 17.5 (16.1-18.8) -1.67 0.07 0.19 0.17-0.22  
Yes 16.2 (14.3-18.2) -0.08 0.12 0.92 0.72-1.17 0.50 
Employed RCVS AVP e None (Intercept) 17.3 (15.9-18.6) -1.69 0.06 0.19 0.16-0.21  
1+ AVP 16.8 (14.8-18.7) -0.04 0.14 0.96 0.73-1.27 0.77 
Employed RCVS specialist 
e 
None (Intercept) 17.1 (16.0-18.2) -1.70 0.06 0.18 0.16-0.21  
1+ specialist 16.5 (12.5-20.5) 0.06 0.34 1.07 0.55-2.06 0.85 
 Continuous factors 
Age (years) Intercept  -1.51 0.06 0.22 0.20-0.25  
Age - linear  -0.38 0.02 0.68 0.66-0.71 <0.01 
Age - quadratic  -0.20 0.01 0.82 0.80-0.83 <0.01 
Age - cubic  0.17 0.01 1.18 1.16-1.20 <0.01 
rIMD f Intercept  -1.69 0.06 0.18 0.17-0.21  
IMD  0.00 0.01 1.00 0.98-1.03 0.83 
Cats per household g Intercept  -1.69 0.06 0.18 0.17-0.21  
Cats per household  0.01 0.02 1.01 0.98-1.04 0.54 
Cats per km2 g Intercept  -1.69 0.06 0.18 0.16-0.21  
Cats per km  -0.01 0.01 0.99 1.00-1.01 0.28 
a 95% Confidence Interval 
b Standard Error 
c Odds Ratio 
d Lipinski et al., 2008 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 
f Rescaled Indices of Multiple Deprivation (rIMD) quintile, 1 = most deprived 









Descriptive summary of the percentage of total sick feline consultations prescribed a topical 
antimicrobial. Also included are parameter estimates from a series of univariable mixed effect 
logistic regression models assessing the association between a range of animal, owner, 
practitioner and practice-related factors and the probability of prescribing a topical 
antimicrobial. Random effects include animal, site, and practice. 
Variable Category % of prescribing 
consults (CI a) 
β SE a OR b CI c P 
 Categorical factors 
Country England (Intercept) 6.0 (5.8-6.3) -2.77 0.02 0.06 0.06-0.07  
Scotland 6.6 (5.5-7.7) 0.07 0.09 1.07 0.90-1.28 0.45 
Wales 6.6 (6.0-7.2) 0.14 0.09 1.15 0.97-1.36 0.11 
Main presenting complaint Gastroenteric (Intercept) 1.1 (0.6-1.6) -4.47 0.10 0.01 0.01-0.01  
Kidney disease  0.8 (0.5-1.1) -0.34 0.23 0.72 0.46-1.11 0.14 
Other unwell 7.1 (6.8-7.4) 1.89 0.10 6.59 5.40-8.04 <0.01 
Pruritus 10.8 (10.0-11.7) 2.35 0.11 10.49 8.54-12.89 <0.01 
Respiratory 5.7 (4.9-6.4) 1.63 0.12 5.10 4.07-6.40 <0.01 
Trauma 4.6 (4.3-5.0) 1.43 0.11 4.20 3.41-5.17 <0.01 
Tumour 1.7 (1.3-2.1) 0.42 0.16 1.53 1.13-2.08 0.01 
Sex Female (Intercept) 6.0 (5.7-6.2) -2.78 0.03 0.06 0.06-0.07  
Male 6.2 (6.0-6.5) 0.04 0.03 1.05 0.99-1.10 0.11 
Neuter status Un-neutered (Intercept) 7.3 (6.8-7.7) -2.57 0.04 0.08 0.07-0.08  
Neutered 5.9 (5.6-6.1) -0.23 0.03 0.79 0.74-0.85 <0.01 
Microchip status Un-microchipped (Intercept) 5.9 (5.7-6.2) -2.79 0.03 0.06 0.06-0.07  
Microchipped 6.4 (6.0-6.7) 0.09 0.03 1.09 1.03-1.16 <0.01 
Vaccination status Un-vaccinated (Intercept) 6.2 (5.9-6.5) -2.74 0.03 0.06 0.06-0.07  
Vaccinated 6.0 (5.8-6.3) -0.02 0.03 0.98 0.93-1.03 0.42 
Insurance status Un-insured (Intercept) 6.3 (6.1-6.5) -2.72 0.02 0.07 0.06-0.07  
Insured 5.3 (4.9-5.8) -0.19 0.04 0.83 0.77-0.89 <0.01 
Owner urban status Urban (Intercept) 6.0 (5.8-6.3) -2.77 0.03 0.06 0.06-0.07  
Rural 6.3 (5.9-6.7) 0.04 0.03 1.04 0.97-1.11 0.26 
Genetic breed group d West Europe (Intercept) 9.5 (8.4-10.6) -2.28 0.05 0.10 0.09-0.11  
Asian 6.9 (5.8-8.0) -0.29 0.09 0.75 0.63-0.88 <0.01 
Crossbreed 5.7 (5.5-5.9) -0.54 0.05 0.58 0.53-0.64 <0.01 
Mediterranean 5.5 (0.5-10.4) -0.47 0.49 0.62 0.24-1.64 0.34 
Unclassified 8.3 (7.2-9.5) -0.13 0.09 0.88 0.74-1.05 0.17 
Unknown 7.4 (6.4-8.3) -0.29 0.08 0.75 0.64-0.88 <0.01 
Practice type Small animal (Intercept) 6.0 (5.8-6.3) -2.77 0.03 0.06 0.06-0.07  
Mixed 6.4 (5.9-7.0) 0.07 0.06 1.08 0.96-1.21 0.20 
Small & equine 5.7 (4.5-6.8) -0.11 0.14 0.89 0.68-1.18 0.43 
Small & large 6.4 (5.5-7.3) 0.09 0.12 1.09 0.86-1.39 0.47 
Accreditation Not accredited (Intercept) 5.9 (5.2-6.5) -2.77 0.06 0.06 0.06-0.07  
1+ accredited site 6.2 (5.9-6.4) 0.02 0.07 1.02 0.90-1.16 0.74 
Hospital status No hospital site (Intercept) 6.0 (5.7-6.2) -2.76 0.03 0.06 0.06-0.07  
1+ hospital site 6.5 (6.1-6.9) 0.04 0.06 1.05 0.94-1.16 0.42 
Referral interest No (Intercept) 6.0 (5.8-6.3) -2.78 0.03 0.06 0.06-0.07  
Yes 6.3 (5.9-6.8) 0.08 0.05 1.08 0.98-1.19 0.10 
Employed RCVS AVP e None (Intercept) 6.1 (5.9-6.4) -2.75 0.03 0.06 0.06-0.07  
1+ AVP 6.0 (5.6-6.4) -0.03 0.05 0.97 0.87-1.08 0.57 
Employed RCVS specialist 
e 
None (Intercept) 6.1 (5.9-6.3) -2.75 0.02 0.06 0.06-0.07  
1+ specialist  5.3 (4.1-6.6) -0.13 0.14 0.88 0.66-1.16 0.36 
 Continuous factors 
Age (years) Intercept  -2.86 0.03 0.06 0.05-0.06  
Age - linear  -0.29 0.03 0.75 0.70-0.79 <0.01 
Age - quadratic  0.04 0.02 1.04 1.01-1.08 0.01 
Age - cubic  -0.04 0.02 0.96 0.93-0.99 0.01 
rIMD f Intercept  -2.76 0.02 0.06 0.06-0.07  
IMD  -0.04 0.02 0.96 0.93-0.99 0.01 
Cats per household g Intercept  -2.75 0.02 0.06 0.06-0.07  
Cats per household  0.01 0.02 1.01 0.97-1.04 0.72 
Cats per km2 g Intercept  -2.75 0.02 0.06 0.06-0.07  
Cats per km  0.01 0.01 1.01 0.98-1.03 0.72 
a 95% Confidence Interval 
b Standard Error 
c Odds Ratio 
d Lipinski et al., 2008 
e Royal College of Veterinary Surgeons (RCVS) Advanced Veterinary Practitioner (AVP) and / or specialist status 




g Aegerter et al., 2017 
 
 
